Transgenic expression of Rspo1 induces significant enlargement of the small and large intestines [4], whereas administration of recombinant or adenoviral Rspo1 alleviates intestinal injury and oral mucositis induced by chemoradiotherapy [5–7]. Here, RSPO1 is linked to oral mucositis.